Last reviewed · How we verify
Merinax (HEXAPROPYMATE)
Merinax (generic name: HEXAPROPYMATE) is a hexapropymate drug. It is currently in Phase 2 development.
Merinax is thought to work by interacting with a specific target in the body, although the exact mechanism is not well understood.
Merinax, also known as hexapropymate, is a small molecule drug of the hexapropymate class. Its exact target and mechanism of action are unknown, and it has not been approved by the FDA for any indications. The commercial status of Merinax is unclear, with no information available on its patent status or generic manufacturers. Further research is needed to determine the safety and efficacy of this compound. As a result, Merinax is not currently available for clinical use.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | HEXAPROPYMATE |
|---|---|
| Drug class | hexapropymate |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like locks, and Merinax is a key that fits into one of those locks. When it binds to the lock, it can affect how the cell works, but we don't know exactly how it does that yet. More research is needed to understand how Merinax works and how it might be used to treat diseases.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Merinax CI brief — competitive landscape report
- Merinax updates RSS · CI watch RSS
Frequently asked questions about Merinax
What is Merinax?
How does Merinax work?
What is the generic name of Merinax?
What drug class is Merinax in?
What development phase is Merinax in?
Related
- Drug class: All hexapropymate drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing